

1 **Supplementary material**

2

3 **Supplementary Table 1.** Summary of baseline patient-, disease- and treatment-related

4 factors associated with serum infliximab trough concentrations quartiles.

	Q1 (N=18)	Q2 (N=17)	Q3 (N=17)	Q4 (N=18)	p^a
Male, (%)	14 (78)	10 (59)	5 (29)	9 (50)	0.035
Age at diagnosis, median (IQR), y	26 (22-41)	24 (19-34)	25 (23-54)	29 (21-44)	0.471
Age at infliximab initiation, median (IQR), y	28 (32-56)	34 (26-43)	38 (33-57)	40 (24-50)	0.552
Disease duration, median (IQR), (years)	1 (3-16)	8 (4-13)	8 (1-13)	5 (2-6)	0.621
Pancolitis ^b , (%)	11 (61)	9 (53)	5 (29)	7 (39)	0.092
Smoking ever, (%)	3 (17)	3 (18)	7 (41)	3 (17)	0.617
Prior infliximab optimization, (%)	10 (56)	12 (71)	10 (59)	11 (61)	0.914
Concomitant IMM ^c , (%)	6 (33)	4 (24)	7 (41)	8 (44)	0.324
BMI, median (IQR), Kg/m ²	25 (22-32)	24 (23-29)	27 (24-28)	25 (23-27)	0.583
CRP >5 mg/L, (%)	1/4 (25)	4/4 (100)	3/3 (100)	2/2 (100)	0.026
Albumin, median (IQR), g/dL	3.8 (3.1-3.9)	4.3 (3.9-4.4)	N/A ^d	4.2 (3.9-4.4)	0.030
ATI, (%)	8/17 (48)	0 (0)	0 (0)	0 (0)	<0.001

5 ^aThe Kruskal-Wallis and the chi-square test (linear-by-linear association) were used to6 compare continuous or discrete variables respectively; ^baccording to Montreal7 classification; ^cthiopurines; ^donly one value.

8 BMI: body mass index; CRP: C-reactive protein; IMM: immunomodulators; IQR:

9 interquartile range; TC: trough concentration; y: years; N/A: not applicable; ATI:

10 antibodies to infliximab.